Research Analysts Set Expectations for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst R. Li forecasts that the company will earn ($1.75) per share for the year. Chardan Capital has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million.

Several other brokerages have also issued reports on STOK. Needham & Company LLC restated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, March 18th. HC Wainwright reissued a “buy” rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $24.67.

Stoke Therapeutics Stock Down 3.2 %

Shares of STOK stock opened at $7.21 on Thursday. The firm has a 50 day moving average of $9.32 and a 200-day moving average of $11.19. The company has a market cap of $389.90 million, a price-to-earnings ratio of -3.43 and a beta of 0.99. Stoke Therapeutics has a 52 week low of $7.06 and a 52 week high of $17.58.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the sale, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. The trade was a 5.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now directly owns 148,253 shares of the company’s stock, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock valued at $143,332 over the last ninety days. Corporate insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Institutional investors have recently modified their holdings of the business. California State Teachers Retirement System raised its stake in shares of Stoke Therapeutics by 16.2% during the 4th quarter. California State Teachers Retirement System now owns 32,068 shares of the company’s stock valued at $354,000 after purchasing an additional 4,468 shares during the period. Toronto Dominion Bank purchased a new position in Stoke Therapeutics in the fourth quarter worth $35,001,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Stoke Therapeutics by 123.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company’s stock valued at $1,053,000 after purchasing an additional 52,813 shares during the last quarter. Squarepoint Ops LLC grew its position in Stoke Therapeutics by 6.7% during the fourth quarter. Squarepoint Ops LLC now owns 120,242 shares of the company’s stock valued at $1,326,000 after acquiring an additional 7,575 shares during the last quarter. Finally, Tang Capital Management LLC purchased a new position in Stoke Therapeutics in the 4th quarter worth $3,309,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.